Comparative Pharmacology
Head-to-head clinical analysis: SATRIC versus TRIMPEX 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SATRIC versus TRIMPEX 200.
SATRIC vs TRIMPEX 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
No standard dosing information available for SATRIC.
200 mg orally once daily, or 100 mg orally twice daily.
None Documented
None Documented
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Terminal elimination half-life is 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with an additional 10-20% as hepatic metabolites excreted in bile and feces.
Category C
Category C
Antiprotozoal, Antibiotic
Antibiotic